Texas Cardiac Arrhythmia Institute leader participates in clinical trial for world's first AI technology for complex cardiac arrhythmia procedures
PR90814
Texas Cardiac Arrhythmia Institute leader participates in clinical trial for world's first artificial intelligence technology for complex cardiac arrhythmia procedures
AUSTIN, Texas, July 23, 2021 /PRNewswire=KYODO JBN/ --
The leader of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's
Medical Center (
https://c212.net/c/link/?t=0&l=en&o=3236884-1&h=4075004528&u=https%3A%2F%2Ftcainstitute.com%2F&a=Texas+Cardiac+Arrhythmia+Institute+(TCAI)+at+St.+David%27s+Medical+Center
) recently led a clinical study to evaluate the world's first data-driven
artificial intelligence (AI) platform for cardiac electrophysiology (EP)
procedures. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac
electrophysiologist and executive medical director of TCAI, conducted the
first-in-human trial in Europe.
The NeuTrace EP Platform technology is designed to better guide
electrophysiologists during complex cardiac EP procedures to help improve
safety and reduce procedure times.
"This first-of-its-kind innovative AI-driven EP platform allows us to enhance
ablation by providing advanced metrics and comprehensive patient data in real
time for a more precise delivery during complex ablation procedures," Dr.
Natale said. "The AI-guided cardiac mapping technology is designed to provide a
much safer option for patients and ensure the best possible outcomes."
The EP platform is built on the foundation of an underlying "Data Biome" and
leverages AI to provide the most high-fidelity signal quality, advanced
metrics, improved visualizations and comprehensive patient data—including real
time, electrical signals and 3-D navigation—for a more accurate view of the
underlying characteristics of the heart during all EP procedures. The mapping
application is one of several "apps" on the EP platform and is designed to
provide a more tailored and accurate approach to mapping and ablation, with the
goal of increasing accuracy and improving patient outcomes—from diagnosis
through ablation and beyond.
The EP platform aims to assist in the treatment of more than 2.7 million
patients in the U.S. with atrial fibrillation, in addition to those who require
ablation procedures. The technology is currently being readied for submission
to the FDA for marketing authorization.
Media Contact:
Tina Shively
Elizabeth Christian Public Relations
TShively@EChristianPR.com
+1.845.216.1850 cell
SOURCE: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。